H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is 1 of the high abbreviated involvement stocks to bargain close now. On November 21, H.C. Wainwright raised the firm’s terms people connected Madrigal Pharmaceuticals to $620 from $568 and maintained a Buy rating. H.C. Wainwright accrued its assumptions for Rezdiffra penetration aft consulting with 6 cardinal sentiment leaders/KOLs. They reported real-world uptake of the cause among patients with metabolic dysfunction-associated steatohepatitis/MASH who person F2/F3 liver fibrosis. Despite competitory unit from value nonaccomplishment medications, the steadfast noted that the KOLs presumption Rezdiffra arsenic an effective, liver-directed, oral backbone therapy that offers broader enlargement possibilities based connected forthcoming F4c data.

Earlier successful its Q3 2025 net call, Madrigal Pharmaceuticals reported important commercialized momentum for its product, Rezdiffra. The institution achieved nett income of $287.3 cardinal for the quarter, marking a 35% sequential increase. The full fig of patients connected Rezdiffra therapy has surpassed 29,500, up from implicit 23,000 successful the erstwhile quarter, with much than 10,000 healthcare providers having prescribed the medication.

Madrigal has made important advancement successful securing marketplace access, achieving wide first-line entree with nary measurement edit requirements successful its payer contracting for 2026. Adherence rates for Rezdiffra are stable, akin to different well-tolerated oral medications, ranging from 60% to 70%. Madrigal is besides focused connected expanding its planetary presence, having successfully launched Rezdiffra successful Germany pursuing European approval. However, the interaction of the EU motorboat connected 2026 maturation is expected to beryllium modest, with the bulk of maturation inactive driven by the US market.

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is simply a biopharmaceutical institution that delivers caller therapeutics for metabolic dysfunction-associated steatohepatitis/MASH successful the US.

While we admit the imaginable of MDGL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.